AstraZeneca to invest $50 bil in U.S. amid tariff threat

AWANI

AstraZeneca plans to invest USD 50 bil in U.S. by 2030 to expand drug manufacturing and research, responding to proposed tariffs on drug imports under the Trump administration.

Transcript

00:00Global pharmaceutical company AstraZeneca plans to invest US$50 billion in the U.S. by 2030

00:07to expand drug manufacturing and research.

00:10It is the latest move by a pharmaceutical company

00:13in response to President Donald Trump's proposed tariffs on drug imports.

00:19The investment will include a new drug facility in Virginia

00:22and expanded R&D as well as cell therapy sites in Maryland, Massachusetts, California, Indiana and Texas.

00:30The company also planned to enhance its U.S. clinical trial supply network

00:34and support development of new medicines.

00:36AstraZeneca said the expansion supports its goal of reaching US$80 billion in annual revenue by 2030,

00:43half of which are from the U.S.

00:45The pledge came on top of the US$3.5 billion investment the company announced in November 2024.

00:52The British-Swedish company is known for co-developing one of the first widely used COVID-19 vaccines.

00:58The move to scale up its U.S. presence is the latest by a drugmaker

01:02as Trump threatens to impose import tariffs as it seeks to boost domestic manufacturing.

01:07half of which they are the two

01:11to the next place

01:14and take typically

01:17and the growing

01:19results

01:19to continue

01:23September 2,

01:25June 26th

01:26September 27th

01:28September 27th

01:29September 27th

01:30September 29th

01:30September 28th

01:31September 23rd

01:32September 23rd

01:33September 27th

01:33September 29th

01:34September 29th

01:34September 22nd

01:36September 28th

Category

Transcript

Be the first to comment

Recommended